Monday, January 02, 2012
Getting Doctors And Patients On The Same Team: A Basketball Metaphor For Health Care - Better Health
....But for the business of medicine, it’s all about the zone.... But what happens when the patients change tactics?.....What if the patient’s psyche or medical issues don’t follow the typical playbook?....So the players become confused.....
Loss of ARID1A protein expression occurs as an early event in ovarian clear-cell carcinoma development and frequently coexists with PIK3CA mutations : Modern Pathology
ARID1A is a recently identified tumor suppressor gene that is mutated in ~50% of ovarian clear-cell carcinomas. This mutation is associated with loss of ARID1A protein expression as assessed by immunohistochemistry. The present study aimed at determining the timing of the loss of ARID1A protein expression during the development of ovarian clear-cell carcinoma and assessing its relevance in correlation to PIK3CA gene mutations......
A Prospective Study of Serum 25-Hydroxyvitamin D (vitamin D) Levels, Blood Pressure, and Incident Hypertension in Postmenopausal Women
authors.....for the Women’s Health Initiative Investigators
In postmenopausal women in this study, serum levels of 25(OH)D were not related to changes in blood pressure, and evidence for an association with lower risk of incident hypertension was weak.
Thanks to the statistics the Blogger software started keeping in May 2009, I know that my blog has reached far from the Garden State. I have also been read in Germany, Great Britain, Russia, Canada, South Korea, France , the Netherlands, Iran and Australia and I have between 1,500 and 2,200 page views a month.....
HE4 is a novel biomarker for ovarian cancer. This study measured HE4 and CA125 levels in women with benign gynecologic disorders.
To establish normal ranges for HE4 serum levels in healthy women.
NEW YORK (Reuters Health) - The coauthor of a study that helped convince the European Commission on Friday to approve bevacizumab (Avastin) as an initial post-surgical treatment for advanced ovarian cancer predicted that some doctors may be reluctant to use the drug until mortality data become available in 2013.......